In this article, we examine the science and policy implications of the common factors perspective (CF; Frank & Frank, 1993; Wampold, 2007). As the empirically supported treatment (EST) approach, grounded in randomized controlled trials (RCTs), is the received view (see Baker, McFall, & Shoham, 2008; McHugh & Barlow, 2012), we make the case for the CF perspective as an additional evidence-based approach for understanding how therapy works, but also as a basis for improving the quality of mental health services. Finally, we argue that it is time to integrate the 2 perspectives, and we challenge the field to do so.
Alex: Welcome to another episode of ResearchPod.
Sam: Today we're looking at a paper that asks a pointed question about psychotherapy: how should we decide whether a treatment actually works? The authors argue the field has been looking at this too narrowly — focusing on one kind of evidence while missing a bigger picture.
Alex: What's the narrow view they're pushing back against?
Sam: The dominant approach treats therapy like a branded product. Each named treatment — say, cognitive behavioral therapy — is seen as a package with special ingredients designed for a specific problem. The gold standard for proving it works is a controlled trial, where one treatment is tested against another under carefully managed conditions. The authors don't reject those trials, but they say treating them as the only valid evidence is a mistake.
Alex: Why is that a problem in practice?
Sam: Because clinics that only chase an approved list of treatments may miss what's actually helping people get better. The paper's central argument is that the goal should be better outcomes for patients — not loyalty to a treatment label.
Alex: So what's the alternative they're proposing?
Sam: They point to something called the common factors view. The idea is that many different therapies help people for the same underlying reasons — a trusting bond between therapist and patient, a clear explanation for why the person is struggling, a believable plan for moving forward, and shared actions the patient actually believes in. Think of it like different sports coaches using completely different drills, but all of them needing the same foundations: trust, structure, and a reason the player buys into.
Alex: So the shared human elements might matter as much as the specific method?
Sam: That's the claim. And the authors are careful to say this isn't an argument that any warm conversation counts as therapy, or that weak treatments are equal to real ones. Their point is narrower: when legitimate therapies work, the shared relational ingredients may be doing a lot of the heavy lifting.
Alex: Which raises the obvious question — what's the evidence that the special ingredients in named treatments are actually doing the work?
Sam: That's exactly where the paper gets interesting. If a treatment's special ingredient is truly essential, then removing it should make the treatment worse. Like a recipe — leave out a key step and the dish should suffer. But the evidence doesn't consistently show that. For depression, one study compared a full cognitive therapy package with a stripped-down version focused only on helping people change their behavior. The stripped-down version did about as well. That suggests the benefit may not be coming from the part the theory said was essential.
Alex: If you can remove the key ingredient and still get results, what is doing the work?
Sam: Probably something broader. The treatment still provides structure, momentum, and a reason to keep going — even without the ingredient that was supposed to be the active part. The same pattern appeared in trauma treatment, where some approaches with no exposure component and no cognitive piece still performed well when therapists delivered them with care and consistency.
Alex: So the label on the treatment may matter less than how it's actually delivered.
Sam: That's the paper's logic. And it connects to something the research consistently shows: the relationship between therapist and patient carries real weight. When the two of them share a trusting bond, agree on what they're working toward, and agree on how they're going to get there, outcomes improve — and that holds even in tightly controlled trials.
Alex: So how do the authors think we should define better care?
Sam: Care that demonstrably helps people improve in real settings — not just in controlled conditions. They argue that means combining useful specific methods with genuine attention to therapist skill, the therapeutic relationship, and the patient's individual situation. A good map matters, but so does the person using it.
Alex: What does that look like in an actual clinic?
Sam: It means tracking progress in real time, using the patient's own improvement as the guide rather than assuming the treatment is working. The paper describes feedback systems that let therapists see when someone is responding well and when they're slipping — so adjustments can be made rather than problems going unnoticed. That kind of check also helps correct for something therapists are prone to: overestimating how well their patients are doing.
Alex: Is the paper saying this approach should replace the named-treatment model?
Sam: No — combine them. The authors are explicit that common factors aren't a defense of vague or unstructured therapy. Their argument is that good outcomes depend on both the specific structure of care and the quality of the human relationship around it. The field has leaned too hard on one kind of proof, and that's made it easy to overlook what actually happens in ordinary practice.
Alex: So the bigger lesson is about what we're measuring and why.
Sam: Exactly. The paper's contribution is to push psychotherapy toward a more practical standard: use evidence, but judge it by patient progress, therapist skill, and how well the treatment fits the person in front of you. That's a measured challenge to the field — and a useful one.
Alex: Thanks for walking us through it.
Sam: Thanks for listening to ResearchPod.